Antisense oligonucleotide modulation of raf gene expression

Details Antisense oligonucleotide modulation of raf gene expression Antisense oligonucleotide modulation of raf gene expression

1998-04-23

1999-12-07

Guzo, David

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

435375, 536 245, A61K 3170, C12N 522, C07H 2100

Patent

active

05998385&

ABSTRACT:
Oligonucleotides are provided which are targeted to nucleic acids encoding human c-raf and capable of inhibiting raf expression. The oligonucleotides contain a methoxyethoxy (2'-O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.

REFERENCES:
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5166195 (1992-11-01), Ecker et al.
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5506212 (1996-04-01), Hoke et al.
patent: 5521302 (1996-05-01), Hoke et al.
patent: 5563255 (1996-10-01), Monia et al.
patent: 5654284 (1997-08-01), Cook et al.
patent: 5656612 (1997-08-01), Monia
patent: 5744362 (1998-04-01), Monia et al.
patent: 5919773 (1999-07-01), Monia et al.
Antisense '97: A roundtable on the state of the industry. Nature Biotechnology 15: 519-524, Apr. 1997.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci. USA 93: 3161-3163, Apr. 1996.
Gura. Antisense has growing pains. Science 270: 575-577, Oct. 1995.
Rojanasakul. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug Delivery Rev., 1996.
Bennett et al., J. Clin. Invest. 1994, 93, 820-828.
BioWorld Today, Apr. 29, 1994, p. 3. It is thus.
Isobe et al., Circulation 1991, 84, 1246-1255.
Kingston, R.E., in Current Protocols in Molecular Biology, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.A. Smith, J.G. Seidman and K. Strahl, eds.) , John Wiley and Sons, NY, 1996.
Martin, P., Helv. Chim. Acta 1995, 78, 486-504.
Rapp et al., The Oncogene Handbook, E.P. Reddy, A.M Skalka and T. Curran, eds., Elsevier Science Publishers, New York, 1988, pp. 213-253.
Riedel et al., Eur. J. Immunol. 1993, 23, 3146-3150.
Sambrook et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, vol. 2, p. 10.59.
Sambrook et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, vol. 2, pp. 11.31-11.32.
Tornkvist et al., J. Biol. Chem. 1994, 269, 13919-13921.

Affiliated with

Also associated with

Rating

Antisense oligonucleotide modulation of raf gene expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotide modulation of raf gene expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide modulation of raf gene expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-823882